Mood Disorders: Depression

Psychiatry: Third Edition

Volumn 1, Issue , 2008, Pages 1283-1331

  Grunze, Heinz ^a   Schüle, Cornelius ^b   Casey, David ^c   Baghai, Thomas C ^b   First, Michael B ^d,e,f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c University of Louisville School of Medicine   (United States)

^d Columbia University ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f NewYork Presbyterian Hospital   (United States)

Author keywords

Antidepressants; Depression; ECT; Epidemiology; Psychotherapy; Suicidality; Unipolar depression

Indexed keywords

EID: 77950807366     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470515167.ch66     Document Type: Chapter

References (535)

1. Abrams R (2002) Electroconvulsive Therapy. Oxford University Press, New York, USA.
2. Abramson LY, Metalsky GI, and Alloy LB (1989) Hopelessness depression: A theory-based subtype of depression. Psychological Review 96, 358-372.
3. Adli M, Baethge C, Heinz A, et al. (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European Archives of Psychiatry and Clinical Neuroscience. 255, 387-400.
4. Adrien J, Dugovic C, and Martin P (1991) Sleep-wakefulness patterns in the helpless rat. Physiology and Behavior 49, 257-262.
5. Agency of Health Care Policy and Research (1993) Depression Guideline Panel: Depression in Primary care: Volume 2, Treatment of major depression. U.S. Department of Health and Human Services, Rockville, MD, USA.
6. Ailawadhi S, Sung KW, Carlson LA, et al. (2007) Serotonin syndrome caused by interaction between citalopram and fentanyl. Journal of Clinical Pharmacy and Therapeutics 32, 199-202.
7. Altshuler LL, Bauer M, Frye MA, et al. (2001) Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry. 158, 1617-1622.
8. American Diabetes Association (2005) Antidepressants associated with increased risk of diabetes in pre-diabetes. http://www.diabetes.org
9. American Psychiatric Association (2000a) Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision. Washington, DC, USA.
10. American Psychiatric Association (2000b) Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 157, 1-45.
11. American Psychiatric Association Committee on Electroconvulsive Therapy, Weiner RD, Coffey CE, Folk J, et al. (2001) The Practice of Elec-troconvulsive Therapy. American Psychiatric Association, Washington, DC, USA.
12. Amin Z, Canli T, and Epperson CN (2005) Effect of estrogen-serotonin interactions on mood and cognition. Behavioral and Cognitive Neuroscience Reviews 4, 43-58.
13. Amsterdam JD (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Journal of Clinical Psychiatry 64, 208-214.
14. Ananth J (1998) Treatment-resistant depression. Psychotherapy and Psy-chosomatics 67, 61-70.
15. Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19-36.
16. Anderson IM, Ferrier N, Baldwin R, et al. (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, in press.
17. Anderson IM, Nutt DJ, and Deakin JF (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. Journal of Psychopharmacology. 14, 3-20.
18. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. (2003) The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. International Journal of Methods in Psychiatric research 12, 3-21.
19. Andrade RJ, Lucena MI, Fernandez MC, et al. (2005) Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129, 512-521.
20. Angst J and Preisig M (1995) Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweizer Archiv fur Neurologie und Psychiatrie 146, 5-16.
21. Angst F, Stassen HH, Clayton PJ, et al. (2002a) Mortality of patients with mood disorders: Follow-up over 34-38 years. Journal of Affective Disorders. 68, 167-181.
22. Angst J, Gamma A, Gastpar M, et al. (2002b) Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies. European Archives of Psychiatry and Clinical Neuroscience. 252, 201-209.
23. Angst J, Angst F, Gerber-Werder R, et al. (2005) Suicide in 406 mood-dis-order patients with and without long-term medication: A 40 to 44 years' follow-up. Archives of Suicide Research 9, 279-300.
24. Arinami T, Li L, Mitsushio H, et al. (1996) An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biological Psychiatry 40, 1122-1127.
25. Artigas F, Adell A, and Celada P (2006) Pindolol augmentation of antidepressant response. Curr. Drug Targets 7, 139-147.
26. Artigas F, Celada P, Laruelle M, et al. (2001) How does pindolol improve antidepressant action? TiPS 22, 224-228.
27. Asberg M, Traskman L, and Thoren P (1976) 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Archives of General Psychiatry 33, 1193-1197.
28. Askew BM (1963) A simple screening procedure for imipramine-like antidepressant agents. Life Sciences 10, 725-730.
29. Baboolal NS (2004) Venlafaxine withdrawal syndrome: Report of seven cases in Trinidad. Journal of Clinical Psychopharmacology 24, 229-231.
30. Baca E, Garcia-Garcia M, and Porras-Chavarino A (2004) Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Progress in NeuroPsychopharmacology and Biological Psychiatry 28, 57-65.
31. Baghai TC, Eser D, Schüle C, et al. (2005) Elektrokonvulsionstherapie bei depressiven Störungen. Journal für Neurologie, Neurochirurgie und Psy-chiatrie 4, 20-28.
32. Baghai TC, Binder EB, Schule C, et al. (2006a) Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Molecular Psychiatry 11, 1003-1015.
33. Baghai TC, Möller H-J, and Rupprecht R (2006b) Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression. Current Pharmaceutical Design 12, 503-515.
34. Baghai TC, Schule C, Zill P, et al. (2004) The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neuroscience Letters 363, 38-42.
35. Baghai TC, Schule C, Zwanzger P, et al. (2002) Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neuroscience Letters 328, 299-303.
36. Baldwin DS (2002) Escitalopram: Efficacy and tolerability in the treatment of depression. Hospital Medicine 63, 668-671.
37. Ban TA (2001) Pharmacotherapy of depression: A historical analysis. Journal of Neural Transmission 108, 707-716.
38. Barbosa L, Berk M, Vorster M (2003) A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 64, 403-407.
39. Barden N, Reul JMHM, and Holsboer F (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences. 18, 6-11.
40. Barrett JE, Williams JW, Jr., Oxman TE, et al. (2001) Treatment of dys-thymia and minor depression in primary care: A randomized trial in patients aged 18 to 59 years. Journal of Family Practice 50, 405-412.
41. Bauer M, Adli M, Baethge C, et al. (2003) Lithium augmentation therapy in refractory depression: Clinical evidence and neurobiological mechanisms. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 48, 440-448.
42. Bauer M, Hellweg R, Graf KJ, et al. (1998) Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18, 444-455.
43. Bauer M, London ED, Rasgon N, et al. (2005) Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Molecular Psychiatry. 10, 456-469.
44. Bauer M, Whybrow PC, Angst J, et al. (2002a) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World Journal of Biological Psychiatry 3, 69-86.
45. Bauer M, Whybrow PC, Angst J, et al. (2002b) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of unipolar depressive disorder, Part 1: Acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry 3, 4-43.
46. Beach S (2003) Affective disorders. Journal of Marital and Family Therapy 29, (2), 247-261.
47. Beck AT, Rush AJ, Shaw BF, et al. (1979) Cognitive Therapy of Depression. Guilford, New York, NY, USA.
48. Beliles K and Stoudemire A (1998) Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 39, S2-19.
49. Bellantuono C, Migliarese G, and Imperadore G (2006) [Pharmacologic therapy of depression during pregnancy]. Recenti Progressi in Medicina 97, 94-107.
50. Benedetti F, Barbini B, Fulgosi MC, et al. (2005) Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: Acute response and long-term remission rates. Journal of Clinical Psychiatry 66, 1535-1540.
51. Bennett DS, Ambrosini PJ, Kudes D, et al. (2005) Gender differences in adolescent depression: Do symptoms differ for boys and girls? J Affect Disord 89, 35-44.
52. Bennett HG and Wyllie AM (1999) Paroxetine and acute angle-closure glaucoma. Eye 13 (Pt. 5), 691-692.
53. Berger M, Vollmann J, Hohagen F, et al. (1997) Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: An open pilot trial in medicated and unmedicated patients. American Journal of Psychiatry 154, 870-872.
54. Berkman LF, Blumenthal J, Burg M, et al. (2003) Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. Journal of the American Medical Association 289, 3106-3116.
55. Berlanga C and Flores-Ramos M (2006) Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Journal of Affective Disorders 95, 119-123.
56. Berman RM, Narasimhan M, Miller HL, et al. (1999) Transient depressive relapse induced by catecholamine depletion: Potential phenotypic vulnerability marker? Archives of General Psychiatry 56, 395-403.
57. Berridge KC and Robinson TE (2003) Parsing reward. Trends in Neuroscience 26, 507-513.
58. Bezchlibnyk-Butler K, Aleksic I, and Kennedy SH (2000) Citalopram-a review of pharmacological and clinical effects. Journal of Psychiatry and Neuroscience. 25, 241-254.
59. Binder EB, Salyakina D, Lichtner P, et al. (2004) Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature Genetics. 36, 1319-1325.
60. Blacker D (1996) Maintenance treatment of major depression: A review of the literature. Harvard Review of Psychiatry 4, 1-9.
61. Blanchard DC, Sakai RR, McEwen B, et al. (1993) Subordination stress: Behavioral, brain, and neuroendocrine correlates. Behavioural Brain Research. 58, 113-121.
62. Blazer DG, Kessler RC, McGonagle KA, et al. (1994) The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. American Journal of Psychiatry. 151, 979-986.
63. Blier P (2003) The pharmacology of putative early-onset antidepressant strategies. European Neuropsychopharmacology. 13, 57-66.
64. Blier P, Saint-Andre E, Hebert C, et al. (2007) Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. International Journal of Neuropsychopharmacology 10, 41-50.
65. Blier P and Ward NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biological Psychiatry. 53, 193-203.
66. Bodkin JA and Amsterdam JD (2002) Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients. American Journal of Psychiatry 159, 1869-1875.
67. Boerner RJ and Möller HJ (1999) The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 32, 119-126.
68. Bogetto F, Bellino S, Revello RB, et al. (2002) Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: A clinical investigation. CNS Drugs 16, 273-283.
69. Bondy B, Baghai TC, Minov C, et al. (2003) Substance P serum levels are increased in major depression: Preliminary results. Biological Psychiatry 53, 538-542.
70. Bondy B, Baghai TC, Zill P, et al. (2005) Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog. Neuropsychopharmacol. Biological Psychiatry 29, 1094-1099.
71. Bonnet U (2003) Moclobemide: Therapeutic use and clinical studies. CNS Drug Rev. 9, 97-140.
72. Bower P and Rowland N (2006) Effectiveness and cost effectiveness of counselling in primary care. The Cochrane Database of Systematic Reviews [Computer File] 3, CD001025.
73. Bowlby J (1980) Attachment and Loss, Vol. 3: Loss: Sadness and Depression. British Journal of Psychiatry 170, 479-482.
74. Boyer EW and Shannon M (2005) The serotonin syndrome. New England Journal Of Medicine. 352, 1112-1120.
75. Brambilla P, Perez J, Barale F, et al. (2003) GABAergic dysfunction in mood disorders. Molecular Psychiatry 8, 721-737, 715.
76. Bridge JA, Iyengar S, Salary CB, et al. (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association 297, 1683-1696.
77. Brion S, Audrain S, and de BC (1996) Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin. Presse Medicale 25, 461-468.
78. Brown CS and Bryant SG.(1988) Monoamine oxidase inhibitors: Safety and efficacy issues. Drug Intelligence and Clinical Pharmacy. 22, 232-235.
79. Brown GK, Beck AT, Steer RA, et al. (2000) Risk factors for suicide in psychiatric outpatients: A 20-year prospective study. Journal of Consulting and Clinical Psychology. 68, 371-377.
80. Bruce ML (2002) Psychosocial risk factors for depressive disorders in late life. Biological Psychiatry. 52, 175-184.
81. Bschor T and Bauer M (2006) Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Current Pharmaceutical Design 12, 2985-2992.
82. Bschor T, Berghofer A, Strohle A, et al. (2002) How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. Journal of Clinical Psychopharmacology. 22, 427-430.
83. Burgess S, Geddes J, Hawton K, et al. (2001) Lithium for maintenance treatment of mood disorders. The Cochrane Database of Systematic Reviews [Computer File] CD003013.
84. Burrows GD, Maguire KP, and Norman TR (1998) Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor rebox-etine: A review. Journal of Clinical Psychiatry 59 (Suppl. 14), 4-7.
85. Burt VK, Suri R, Altshuler L, et al. (2001) The use of psychotropic medications during breast-feeding. American Journal of Psychiatry 158, 1001-1009.
86. Butt AA, Evans R, Skanderson M, et al. (2006) Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. Journal of Hepatology 44, 864-868.
87. Cairncross KD, Cox B, Forster C, et al. (1977) The olfactory bulbectomized rat: A simple model for detecting drugs with antidepressant potential [proceedings]. British Journal of Pharmacology 61, 497P.
88. Calabrese JR, Bowden CL, Sachs GS, et al. (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 60, 79-88.
89. Calil HM (2001) Fluoxetine: A suitable long-term treatment. Journal of Clinical Psychiatry 62 (Suppl. 22), 24-29.
90. Camp NJ, Lowry MR, Richards RL, et al. (2005) Genome-wide linkage analyses of extended Utah pedigrees identifies loci that influence recurrent, early-onset major depression and anxiety disorders. American Journal of Medical Genetics. B Neuropsychiatry Genetics 135, 85-93.
91. Campo-Arias A (2004) Antidepressants in migraine prophylaxis: An approximation. Revista De Neurologia. 38, 864-868.
92. Carney RM, Blumenthal JA, Freedland KE, et al. (2004) Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosomatic Medicine 66, 466-474.
93. Carrasco GA, Barker SA, Zhang Y, et al. (2004) Estrogen treatment increases the levels of regulator of G protein signaling-Z1 in the hypothalamic paraventricular nucleus: Possible role in desensitization of 5-hydroxytryp-tamine1A receptors. Neuroscience 127, 261-267.
94. Carroll BJ and Rubin RT (2007) Mifepristone in Psychotic Depression? Biological Psychiatry.
95. Caspi A, Sugden K, Moffitt TE, et al. (2003) Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389.
96. Casten RJ, Rovner BW, and Tasman W (2004) Age-related macular degeneration and depression: A review of recent research. Current Opinion in Ophthalmology 15, 181-183.
97. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine. 354, 579-587.
98. Cheeta S, Schifano F, Oyefeso A, et al. (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. British Journal of Psychiatry 184, 41-47.
99. Cheetham SC, Katona CLE, and Horton RW (1991) Biological aspects of affective disorders, Horton RW and Katona CLE. (eds). Academic Press, London, UK, pp 192-221.
100. Chiu HF (1997) Antidepressants in the elderly. International Journal of Clinical Practice. 51, 369-374.
101. Chopra MP, Zubritsky C, Knott K, et al. (2005) Importance of subsyn-dromal symptoms of depression in elderly patients. American Journal of Geriatric Psychiatry 13, 597-606.
102. Cipriani A, Barbui C, Brambilla P, et al. (2006) Are All Antidepressants Really the Same? The Case of Fluoxetine: A Systematic Review. Journal of Clinical Psychiatry 67, 850-864.
103. Ciusani E, Zullino DF, Eap CB, et al. (2004) Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: Pharmacokinetic and clinical aspects. Journal of Psychopharmacology 18, 559-566.
104. Clark RE, Xie H, and Brunette MF (2004) Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. Journal of Clinical Psychiatry 65, 151-155.
105. Clayton AH, Zajecka J, Ferguson JM, et al. (2003) Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International Clinical Psychopharmacology 18, 151-156.
106. Cohen LS, Nonacs R, Viguera AC, et al. (2004) Diagnosis and treatment of depression during pregnancy. CNS Spectrums 9, 209-216.
107. Conley RR, scher-Svanum H, Zhu B, et al. (2007) The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophrenia Research 90, 186-197.
108. Coppell AL, Pei Q, and Zetterstrom TS (2003) Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44, 903-910.
109. Coppen A (1967) The biochemistry of affective disorders. British Journal of Psychiatry 113, 1237-1264.
110. Corruble E and Guelfi JD (2000) Does increasing dose improve efficacy in patients with poor antidepressant response: A review. Acta Psychiatrica Scandinavica. 101, 343-348.
111. Coryell W (1996) Psychotic depression. Journal of Clinical Psychiatry 57 (Suppl. 3), 27-31.
112. Craft LL and Perna FM (2004) The Benefits of Exercise for the Clinically Depressed. Prim. Care Companion. Journal of Clinical Psychiatry 6, 104-111.
113. Cuijpers P, de GR, and van DS (2004) Minor depression: Risk profiles, functional disability, health care use and risk of developing major depression. Journal of Affective Disorders 79, 71-79.
114. Cuijpers P, Smit F, and van SA (2007) Psychological treatments of subthreshold depression: A meta-analytic review. Acta Psychiatrica Scandi-navica 115, 434-441.
115. Cummings JL and Masterman DL (1999) Depression in patients with Parkinson's disease. International Journal of Geriatric Psychiatry 14, 711-718.
116. Cuzzell JZ (2006) Paroxetine may increase risk for congenital malformations. Dermatology Nursing 18, 68.
117. Cyr M and Brown CS (1996) Nefazodone: Its place among antidepressants. Annals of Pharmacotherapy 30, 1006-1012.
118. Danish University Antidepressant Group (1993) Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. Journal of Affective Disorders 28, 105-116.
119. Davis LL, Frazier E, Husain MM, et al. (2006) Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort. American Journal on Addictions 15, 278-285.
120. Dawson LA and Nguyen HQ (2000) The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: The mechanism of action of (+/-)pindolol. Neuropharmacology 39, 1044-1052.
121. de la Gandara J, Aguera L, Rojo JE, et al. (2005) Use of antidepressant combinations: Which, when and why? Results of a Spanish survey. Acta Psychiatrica Scandinavica 112 (Suppl. 428) 32-36.
122. de Maat SM, Dekker J, Schoevers RA, et al. (2007) Relative efficacy of psychotherapy and combined therapy in the treatment of depression: A meta-analysis. European Psychiatry. Journal of the Association of European Psychiatrists 22, 1-8.
123. De Mello ME, de Jesus M, Bacaltchuk J, et al. (2005) A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. European Archives of Psychiatry and Clinical Neuroscience 255 (2), 75-82.
124. Degner D, Grohmann R, Kropp S, et al. (2004) Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37 (Suppl. 1), S39-S45.
125. Delgado PL (2000) Depression: The case for a monoamine deficiency. Journal of Clinical Psychiatry 61 (Suppl. 6), 7-11.
126. Deltito J and Beyer D (1998) The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. Journal of Affective Disorders 51, 345-351.
127. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. (2004) Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Journal of the American Medical Association 291, 2581-2590.
128. Depression Guideline Panel (1993) Depression in Primary Care: Vol. 1. Detection and Diagnosis. Public Health Agency, Agency for Health Care and Policy Research, Washington, DC, USA.
129. Devanand DP, Sackeim HA, and Prudic J (1991) Electroconvulsive therapy in the treatment-resistant patient. Psychiatric Clinics of North America 14, 905-923.
130. DeVane CL, Grothe DR, and Smith SL (2002) Pharmacology of antidepressants: Focus on nefazodone. Journal of Clinical Psychiatry 63 (Suppl. 1), 10-17.
131. Dietrich DE and Emrich HM (1998) The use of anticonvulsants to augment antidepressant medication. Journal of Clinical Psychiatry 59 (Suppl. 5), 51-58.
132. Dilsaver SC (1988) Monoamine oxidase inhibitor withdrawal phenomena: Symptoms and pathophysiology. Acta Psychiatrica Scandinavica 78, 1-7.
133. Dinan TG (1998) Psychoneuroendocrinology of depression. Growth hormone. Psychiatric Clinics of North America 21, 325-339.
134. Dingemanse J, Wallnofer A, Gieschke R, et al. (1998) Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome". Clinical Pharmacology and Therapeutics 63, 403-413.
135. Dodd S, Horgan D, Malhi GS, et al. (2005) To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders. 89, 1-11.
136. Drevets WC (2000) Neuroimaging studies of mood disorders. Biological Psychiatry. 48, 813-829.
137. Duggal HS, Gates C, Pathak PC (2004) Olanzapine-induced neutropenia: Mechanism and treatment. Journal of Clinical Psychopharmacology 24, 234-235.
138. Duman RS (2002) Synaptic plasticity and mood disorders. Molecular Psychiatry 7 (Suppl. 1), S29-S34.
139. Dunlop BW and Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Archives of General Psychiatry 64, 327-337.
140. Ebmeier KP, Donaghey C, and Steele JD (2006) Recent developments and current controversies in depression. Lancet 367, 153-167.
141. ECT review group (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet 361, 799-808.
142. Ehlers CL and Kupfer DJ (1987) Hypothalamic peptide modulation of EEG sleep in depression: A further application of the S-process hypothesis. Biological Psychiatry 22, 513-517.
143. Ehlers CL, Frank E, and Kupfer DJ (1988) Social Zeitgebers and biological rhythms. Archives of General Psychiatry 45, 948-952.
144. Einarson TR and Einarson A (2005) Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiology and Drug Safety 14, 823-827.
145. Ellis P (2004) Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 38, 389-407.
146. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. (1998) Neurogenesis in the adult human hippocampus. Nature Medicine 4, 1313-1317.
147. Evans DL, Charney DS, Lewis L, et al. (2005) Mood disorders in the medically ill: Scientific review and recommendations. Biological Psychiatry 58, 175-189.
148. Fallon BA and Nields JA (1994) Lyme disease: A neuropsychiatric illness. American Journal of Psychiatry 151, 1571-1583.
149. Fava GA (2003) Can long-term treatment with antidepressant drugs worsen the course of depression? Journal of Clinical Psychiatry 64, 123-133.
150. Fava M (2002) Somatic symptoms, depression, and antidepressant treatment. Journal of Clinical Psychiatry 63, 305-307.
151. Fava M, Rush AJ, Wisniewski SR, et al. (2006) A comparison of mirtaza-pine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. American Journal of Psychiatry 163, 1161-1172.
152. Fava M, Thase ME, DeBattista C, et al. (2007) Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Annals of Clinical Psychiatry 19, 153-159.
153. Fergusson D, Doucette S, Glass KC, et al. (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. British Medical Journal 330, 396-399.
154. Fink HA, MacDonald R, Rutks IR, et al. (2003) Trazodone for erectile dysfunction: A systematic review and meta-analysis. BJU International 92, 441-446.
155. Fink M, Abrams R, Bailine S, et al. (1996) Ambulatory electroconvulsive therapy: Report of a task force of the association for convulsive therapy. Association for Convulsive Therapy. Convulsive Therapy 12, 42-55.
156. Foley KF, DeSanty KP, and Kast RE. (2006) Bupropion: Pharmacology and therapeutic applications. Expert Review of Neurotherapeutics 6, 1249-1265.
157. Fountoulakis KN, Iacovides A, Nimatoudis I, et al. (1999) Comparison of the diagnosis of melancholic and atypical features according to DSM-IV and somatic syndrome according to ICD-10 in patients suffering from major depression. European Psychiatry: The Journal of the Association of European Psychiatrists 14, 426-433.
158. Franchini L, Gasperini M, Perez J, et al. (1998) Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, doubleblind study. Journal of Clinical Psychiatry 59, 229-232.
159. Francis DD, Caldji C, Champagne F, et al. (1999a) The role of corticotropin-releasing factor-norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress. Biological Psychiatry. 46, 1153-1166.
160. Francis DD, Champagne FA, Liu D, et al. (1999b) Maternal care, gene expression, and the development of individual differences in stress reactivity. Annals of the New York Academy of Sciences 896:66-84., 66-84.
161. Franco-Bronson K (1996) The management of treatment-resistant depression in the medically ill. Psychiatric Clinics of North America 19, 329-350.
162. Frank E (2007) Interpersonal and social rhythm therapy: A means of improving depression and preventing relapse in bipolar disorder. Journal of Clinical Psychology 63, 463-473.
163. Frank E, Kupfer DJ, Buysse DJ, et al. (2007) Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. American Journal of Psychiatry 164, 761-767.
164. Frank E, Kupfer DJ, Perel JM, et al. (1990) Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry 47, 1093-1099.
165. Frank E, Kupfer DJ, Thase ME, et al. (2005) Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Archives of General Psychiatry 62, 996-1004.
166. Frasure-Smith N, Lesperance F, and Julien P (2004) Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biological Psychiatry 55, 891-896.
167. Freeman MP, Hibbeln JR, Wisner KL, et al. (2006) Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatrica Scandinavica 113, 31-35.
168. Freud S (1917) Trauer und Melancholie. Psychologie des Unbewussten. Fischer, Frankfurt a. Main.
169. Frodl T, Meisenzahl EM, Zetzsche T, et al. (2002) Hippocampal changes in patients with a first episode of major depression. American Journal Of Psychiatry 159, 1112-1118.
170. Furukawa T, McGuire H, and Barbui C (2003) Low dosage tricyclic antidepressants for depression. The Cochrane Database of Systematic Reviews [Computer File] CD003197.
171. Furukawa T, Streiner DL, and Young LT (2000) Antidepressant plus benzodiazepine for major depression. Cochrane Database of Systematic Reviews [Computer File] CD001026.
172. Furukawa TA, Streiner DL, and Young LT (2001) Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. Journal of Affective Disorders 65, 173-177.
173. Gallagher P and Young AH (2006) Mifepristone (RU-486) treatment for depression and psychosis: A review of the therapeutic implications. Neuropsychiatric Disease and Treatment, 2, 33-42.
174. Gardner DM and Lynd LD (1998) Sumatriptan contraindications and the serotonin syndrome. Annals of Pharmacotherapy 32, 33-38.
175. Garlow SJ, Musselman DL, and Nemeroff CB (1999) Neurobiology of mental illness, Charney DS, Nestler EJ, and Bunney BS (eds). Oxford University Press, Oxford, UK, pp 348-364.
176. Garner EM, Kelly MW, and Thompson DF (1993) Tricyclic antidepressant withdrawal syndrome. Annals of Pharmacotherapy 27, 1068-1072.
177. Geddes JR, Carney SM, Davies C, et al. (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 361, 653-661.
178. Geddes JR, Freemantle N, Mason J, et al. (2000) SSRIs versus other antidepressants for depressive disorder. The Cochrane Database of Systematic Reviews [Computer File] CD001851.
179. Ghaziuddin N, Laughrin D, and Giordani B (2000) Cognitive side effects of electroconvulsive therapy in adolescents. Journal of Child and Adolescent Psychopharmacology 10, 269-276.
180. Gibbons RD, Brown CH, Hur K, et al. (2007) Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164, 1356-1363.
181. Gillman PK (1999) The serotonin syndrome and its treatment. Journal of Psychopharmacology 13, 100-109.
182. Gilmer WS, Trivedi MH, Rush AJ, et al. (2005) Factors associated with chronic depressive episodes: A preliminary report from the STAR-D project. Acta Psychiatrica Scandinavica 112, 425-433.
183. Glassman AH, Bigger JT, Gaffney M, et al. (2006) Onset of major depression associated with acute coronary syndromes: Relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Archives of General Psychiatry 63, 283-288.
184. Golden RN, Gaynes BN, Ekstrom RD, et al. (2005) The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. American Journal of Psychiatry 162, 656-662.
185. Goldney RD (2006) Suicide and antidepressants: What is the evidence? Australian and New Zealand Journal of Psychiatry 40, 381-385.
186. Goodwin F, Ebert M, and Bunney W (1972) Psychiatric complications of medical drugs. Shader F (ed). Raven, New York, NY, USA, pp 73-101.
187. Goodwin GM (2003) Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 17, 149-173.
188. Green B (2003) Focus on paroxetine. Current Medical Research and Opinion 19, 13-21.
189. Greenhalgh J, Knight C, Hind D, et al. (2005) Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: Systematic reviews and economic modelling studies. Health Technology Assessment: HTA/NHS R&D HTA Programme 9, 1-iv.
190. Griffith JD, Carranza J, Griffith C, et al. (1983) Bupropion: Clinical assay for amphetamine-like abuse potential. Journal of Clinical Psychiatry 44, 206-208.
191. Grigoriadis S, Kennedy SH, Srinivisan J, et al. (2005) Antidepressant augmentation with raloxifene. Journal of Clinical Psychopharmacology 25, 96-98.
192. Grunebaum MF, Ellis SP, Li S, et al. (2004) Antidepressants and suicide risk in the United States, 1985-1999. Journal of Clinical Psychopharmacology 65, 1456-1462.
193. Grunhaus L, Pande AC, Brown MB, et al. (1994) Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. American Journal of Psychiatry 151, 541-546.
194. Grunhaus L, Rabin D, and Greden JF (1986) Simultaneous panic and depressive disorder: Response to antidepressant treatments. Journal of Clinical Psychiatry 47, 4-7.
195. Gunderson JG and Phillips KA (1991) A current view of the interface between borderline personality disorder and depression. American Journal of Psychiatry 148, 967-975.
196. Gunnell D, Saperia J, and Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. British Medical Journal 330, 385.
197. Guzzetta F, Tondo L, Centorrino F, et al. (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. Journal of Clinical Psychiatry 68, 380-383.
198. Haavisto A, Sourander A, Ellila H, et al. (2003) Suicidal ideation and suicide attempts among child and adolescent psychiatric inpatients in Finland. Journal of Affective Disorders 76, 211-221.
199. Haddad P (1998) The SSRI discontinuation syndrome. Journal of Psychopharmacology 12, 305-313.
200. Hairston IS, Peyron C, Denning DP, et al. (2004) Sleep deprivation effects on growth factor expression in neonatal rats: A potential role for BDNF in the mediation of delta power. Journal of Neurophysiology 91, 1586-1595.
201. Halbreich U and Kahn LS (2006) Atypical depression, somatic depression and anxious depression in women: Are they gender-preferred phenotypes? Journal of Affective Disorders.
202. Hall WD and Lucke J (2006) How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Australian and New Zealand Journal of Psychiatry 40, 941-950.
203. Hameed U, Schwartz TL, Malhotra K, et al. (2005) Antidepressant treatment in the primary care office: Outcomes for adjustment disorder versus major depression. Annals of Clinical Psychiatry 17, 77-81.
204. Hamilton M (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
205. Hamilton M (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
206. Hammad TA, Laughren TP, and Racoosin JA (2006) Suicide rates in shortterm randomized controlled trials of newer antidepressants. Journal of Clinical Psychopharmacology 26, 203-207.
207. Hansen RA, Gartlehner G, Lohr KN, et al. (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 143, 415-426.
208. Haria M, Fitton A, and McTavish D (1994) Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4, 331-355.
209. Harvey BH, McEwen BS, and Stein DJ (2003) Neurobiology of antidepressant withdrawal: Implications for the longitudinal outcome of depression. Biological Psychiatry. 54, 1105-1117.
210. Hashimoto K, Sawa A, and Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry. 62, 1310-1316.
211. Hasin DS, Goodwin RD, Stinson FS, et al. (2005) Epidemiology of major depressive disorder: Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Archives of General Psychiatry 62, 1097-1106.
212. Hatzinger M, Hemmeter UM, Baumann K, et al. (2002) The combined DEX-CRH test in treatment course and long-term outcome of major depression. Journal of Psychiatric Research 36, 287-297.
213. Hazell P, O'Connell D, Heathcote D, et al. (2002) Tricyclic drugs for depression in children and adolescents. The Cochrane Database of Systematic Reviews [Computer File] CD002317.
214. Healy D and Whitaker C (2003) Antidepressants and suicide: Risk-benefit conundrums. Journal of Psychiatry and Neuroscience 28, 331-337.
215. Heim C and Nemeroff CB (2001) The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. Biological Psychiatry. 49, 1023-1039.
216. Henkel V, Mergl R, Allgaier AK, et al. (2006) Treatment of depression with atypical features: A meta-analytic approach. Psychiatry Research. 141, 89-101.
217. Henkel V and Möller H-J (2005) What are the most effective diagnostic and therapeutic strategies for the management of depression in specialist care? http://www.euro.who.int/document/e86602.pdf
218. Hibbeln JR (1998) Fish consumption and major depression. Lancet 351, 1213.
219. Hickie I, Scott E, Naismith S, et al. (2001) Late-onset depression: Genetic, vascular and clinical contributions. Psychological Medicine 31, 1403-1412.
220. Hildebrandt MG, Steyerberg EW, Stage KB, et al. (2003) Are gender differences important for the clinical effects of antidepressants? American Journal of Psychiatry 160, 1643-1650.
221. Hirschfeld RM (2000) Antidepressants in long-term therapy: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica 403(Suppl.), 35-38.
222. Hirschfeld RM (2001) Clinical importance of long-term antidepressant treatment. British Journal of Psychiatry 42 (Suppl.), S4-S8.
223. Hirschfeld RM, Montgomery SA, Aguglia E, et al. (2002) Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. Journal of Clinical Psychiatry 63, 826-837.
224. Hirschfeld RM and Vornik LA (2004) Newer antidepressants: Review of efficacy and safety of escitalopram and duloxetine. Journal of Clinical Psychiatry 65 (Suppl. 4), 46-52.
225. Hollon SD, Jarrett RB, Nierenberg AA, et al. (2005) Psychotherapy and medication in the treatment of adult and geriatric depression: Which monotherapy or combined treatment? Journal of Clinical Psychiatry 66, 455-468.
226. Horne RL, Ferguson JM, Pope HG, Jr., et al. (1988) Treatment of bulimia with bupropion: A multicenter controlled trial. Journal of Clinical Psychiatry 49, 262-266.
227. Horowitz A, Reinhardt JP, Kennedy GJ (2005) Major and subthreshold depression among older adults seeking vision rehabilitation services. American Journal of Geriatric Psychiatry 13, 180-187.
228. Hudson JI, Mangweth B, Pope HG, Jr., et al. (2003) Family study of affective spectrum disorder. Archives of General Psychiatry 60, 170-177.
229. Huibers MJ, Beurskens AJ, Bleijenberg G, et al. (2003) The effectiveness of psychosocial interventions delivered by general practitioners. The Cochrane Database of Systematic Reviews [Computer File] CD003494.
230. Hung CI, Liu CY, Fuh JL, et al. (2006) Comorbid migraine is associated with a negative impact on quality of life in patients with major depression. Cephalalgia 26, 26-32.
231. Hurley SC (2002) Lamotrigine update and its use in mood disorders. Annals of Pharmacotherapy 36, 860-873.
232. Husain MM, Rush AJ, Sackeim HA, et al. (2005) Age-related characteristics of depression: A preliminary STAR*D report. American Journal of Geriatric Psychiatry 13, 852-860.
233. Hutton HE, Lyketsos CG, Zenilman JM, et al. (2004) Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. American Journal of Psychiatry 161, 912-914.
234. Invernizzi G, Aguglia E, Bertolino A, et al. (1994) The efficacy and safety of tianeptine in the treatment of depressive disorder: Results of a controlled double-blind multicentre study vs. amitriptyline. Neuropsychobiology 30, 85-93.
235. Jahn H, Schick M, Kiefer F, et al. (2004) Metyrapone as additive treatment in major depression: A double-blind and placebo-controlled trial. Archives of General Psychiatry 61, 1235-1244.
236. Jann MW and Slade JH (2007) Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 27, 1571-1587.
237. Jin H, Hampton AJ, Yu X, et al. (2006) Depression and suicidality in HIV/ AIDS in China. Journal of Affective Disorders 94, 269-275.
238. Jorge RE, Robinson RG, Arndt S, et al. (2003) Mortality and poststroke depression: A placebo-controlled trial of antidepressants. American Journal of Psychiatry 160, 1823-1829.
239. Joyce PR, Mulder RT, Luty SE, et al. (2003) Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. International Journal of Neuropsychopharmacology 6, 339-346.
240. Judd LL, Akiskal HS, Maser JD, et al. (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry 55, 694-700.
241. Kachkovskii MA and Kriukov NN (2006) [Treatment of depression in patients with myocardial infarction with tianeptine]. Kardiologiia 46, 21-26.
242. Kahn LS and Halbreich U (2005) Estrogen effects in psychiatric disorders. Bergemann N and Riecher-Rossler A (eds). Springer Verlag, Wien, New York, NY, USA, pp 145-173.
243. Kanner AM (2005a) Depression in epilepsy: A neurobiologic perspective Epilepsy Currents 5, 21-27.
244. Kanner AM (2005b) Should neurologists be trained to recognize and treat comorbid depression of neurologic disorders? Yes. Epilepsy Behavior 6, 303-311.
245. Karasu TB, Docherty JP, Gelenberg A, et al. (1993) Practice guideline for major depressive disorder in adults. American Psychiatric Association. American Journal of Psychiatry 150, 1-26.
246. Karp JF, Scott J, Houck P, et al. (2005) Pain predicts longer time to remission during treatment of recurrent depression. Journal of Clinical Psychiatry 66, 591-597.
247. Kashani JH, Carlson GA, and Beck, NC (1987) Depression, depressive symptoms, and depressed mood among a community sample of adolescents. American Journal of Psychiatry 144, 931-934.
248. Kasper S (2001) Hypericum perforatum-a review of clinical studies. Pharmacopsychiatry 34 (Suppl. 1), S51-S55.
249. Kasper S and Olie JP (2002) A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. European Psychiatry: The Journal of the Association of European Psychiatrists 17 (Suppl 3), 331-340.
250. Kasper S, Spadone C, Verpillat P, et al. (2006) Onset of action of escitalo-pram compared with other antidepressants: Results of a pooled analysis. International Clinical Psychopharmacology 21, 105-110.
251. Kato T (2001) Molecular genetics of bipolar disorder. Neuroscience Research 40, 105-113.
252. Katona CL (1997) Depression and Physical Illness. John Wiley & Sons Ltd, Chichester, UK.
253. Kelder J, Funke C, De BT, et al. (1997) A comparison of the physicochemical and biological properties of mirtazapine and mianserin. Journal of Pharmacy and Pharmacology 49, 403-411.
254. Keller M, Montgomery S, Ball W, et al. (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry 59, 216-223.
255. Kellner CH, Fink M, Knapp R, et al. (2005) Relief of expressed suicidal intent by ECT: A consortium for research in ECT study. American Journal of Psychiatry 162, 977-982.
256. Kellner CH, Knapp RG, Petrides G, et al. (2006) Continuation electro-convulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the Consortium for Research in Elec-troconvulsive Therapy (CORE). Archives of General Psychiatry 63, 1337-1344.
257. Kelly JP, Wrynn AS, and Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: An update. Pharmacology and Therapeutics 74, 299-316.
258. Kendler KS (1998) Gender differences in the genetic epidemiology of major depression. Journal of Gender-Specific Medicine 1, 28-31.
259. Kendler KS, Thornton LM, and Gardner CO (2000) Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the "kindling" hypothesis. American Journal of Psychiatry 157, 1243-1251.
260. Kendler KS, Thornton LM, and Prescott CA (2001) Gender differences in the rates of exposure to stressful life events and sensitivity to their depressogenic effects. American Journal of Psychiatry 158, 587-593.
261. Kennedy SH, Lam RW, Cohen NL, et al. (2001) Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 46 (Suppl 1), 38S-58S.
262. Kent JM (2000) SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet 355, 911-918.
263. Kessler RC (2003) Epidemiology of women and depression. Journal of Affective Disorders 74, 5-13.
264. Kessler RC (1997) The effects of stressful life events on depression. Annual Review of Psychology 48, 191-214.
265. Kessler RC, Berglund P, Demler O, et al. (2003) The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095-3105.
266. Kessler RC, Zhao S, Blazer DG, et al. (1997) Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. Journal of Affective Disorders 45, 19-30.
267. Khan A, Brodhead AE, Schwartz KA, et al. (2005) Sex differences in antidepressant response in recent antidepressant clinical trials. Journal of Clinical Psychopharmacology 25, 318-324.
268. Khouzam HR, Emes R, Gill T, et al. (2003) The antidepressant sertraline: A review of its uses in a range of psychiatric and medical conditions. Comprehensive Therapy 29, 47-53.
269. Kim DK, Lim SW, Lee S, et al. (2000) Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11, 215-219.
270. Kimmel PL and Peterson RA (2005) Depression in end-stage renal disease patients treated with hemodialysis: Tools, correlates, outcomes, and needs. Seminars in Dialysis 18, 91-97.
271. King DE, Finestone DH, and Peden JG (1994) Combination antidepressant therapy in primary care. Archives of Family Medicine 3, 1088-1092.
272. Kitada M (2003) Genetic polymorphism of cytochrome P450 enzymes in Asian populations: Focus on CYP2D6. International Journal of Clinical Pharmacology Research 23, 31-35.
273. Klerman GI, Weissman MM, Rousaville BJ, et al. (1984) Interpersonal Psychotherapy of Depression. Basic Books, New York, NY, USA.
274. Klerman GL, Budman S, Berwick D, et al. (1987) Efficacy of a brief psychosocial intervention for symptoms of stress and distress among patients in primary care. Medical Care 25, 1078-1088.
275. Kohut (1971) The Analysis of the Self. International Universities Press, New York, NY, USA.
276. Kornstein SG, Schatzberg AF, Thase ME, et al. (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. American Journal of Psychiatry 157, 1445-1452.
277. Kornstein SG, Sloan DM, and Thase ME (2002) Gender-specific differences in depression and treatment response. Psychopharmacology Bulletin 36, 99-112.
278. Koski A, Vuori E, and Ojanpera I (2005) Newer antidepressants: Evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. International Journal of Legal Medicine 119, 344-348.
279. Krystal A, Thase M, Tucker V, et al. (2007) Bupropion HCL and sleep in patients with depression. Current Psychiatric Reviews 3 (2), 123-128.
280. Kuehner C (2003) Gender differences in unipolar depression: An update of epidemiological findings and possible explanations. Acta Psychiatrica Scandinavica 108, 163-174.
281. Kugaya A, Seneca NM, Snyder PJ, et al. (2003) Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28, 413-420.
282. Kuhs H, Kemper B, Lippe-Neubauer U, et al. (1998) Repeated sleep deprivation once versus twice a week in combination with amitriptyline. Journal of Affective Disorders 47, 97-103.
283. Kupfer DJ (1991) Long-term treatment of depression. Journal of Clinical Psychiatry 52(Suppl), 28-34.
284. Kupfer DJ (2005) The pharmacological management of depression. Dialogues in Clinical Neuroscience 7, 191-205.
285. Laakmann G, Faltermaier-Temizel M, Bossert-Zaudig S, et al. (1996) Are benzodiazepines antidepressants? Psychopharmacology (Berl. ) 124, 291-292.
286. Lader MH (1996) Tolerability and safety: Essentials in antidepressant pharmacotherapy. Journal of Clinical Psychiatry 57 (Suppl. 2), 39-44.
287. Lam RW, Levitan RD, Tam EM, et al. (1997) L-tryptophan augmentation of light therapy in patients with seasonal affective disorder. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 42, 303-306.
288. Lambert MT, Trutia C, and Petty F (1998) Extrapyramidal adverse effects associated with sertraline. Progress in Neuro-Psychopharmacology and Biological Psychiatry 22, 741-748.
289. Lara ME and Klein DN (1999) Psychosocial processes underlying the maintenance and persistence of depression: Implications for understanding chronic depression. Clinical Psychology Review 19, 553-570.
290. Larsen JK (1988) MAO inhibitors: Pharmacodynamic aspects and clinical implications. Acta Psychiatrica Scandinavica 345 (Suppl.), 74-80.
291. Lederbogen F, Deuschle M, and Heuser I (1999) Depression-a cardiovascular risk factor] Internist (Berl. ) 40, 1119-1121.
292. Lee MS, Lim SW, Cha JH, et al. (2006) Korean Medication Algorithm for Major Depressive Disorder. International Journal of Psychiatry in Clinical Practice 10, 186-194.
293. Leichsenring F (2005) Are psychodynamic and psychoanalytic therapies effective?: A review of empirical data. International Journal of PsychoAnalysis 86, 841-868.
294. Leichsenring F, Hiller W, Weissberg M, et al. (2006) Cognitive-behavioral therapy and psychodynamic psychotherapy: Techniques, efficacy, and indications. American Journal of Psychotherapy 60, 233-259.
295. Leonard BE (2000) Evidence for a biochemical lesion in depression. Journal of Clinical Psychiatry 61 (Suppl. 6), 12-17.
296. Lesch KP, Bengel D, Heils A, et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531.
297. Lieb K, Walden J, Grunze H, et al. (2004) Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry 37, 238-239.
298. Lieberman A (2006) Depression in Parkinson's disease-a review. Acta Neurologica Scandinavica 113, 1-8.
299. Linde K, Berner M, Egger M, et al. (2005) St John's wort for depression: Meta-analysis of randomised controlled trials. British Journal of Psychiatry 186, 99-107.
300. Linkowski P, Mendlewicz J, Kerkhofs M, et al. (1987) 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: Effect of antidepressant treatment. Journal of Clinical Endocrinology and Metabolism 65, 141-152.
301. Linnoila M, Cowdry R, Lamberg BA, et al. (1983) CSF triiodothyronine (rT3) levels in patients with affective disorders. Biological Psychiatry 18, 1489-1492.
302. Lisanby SH, Maddox JH, Prudic J, et al. (2000) The effects of electroconvul-sive therapy on memory of autobiographical and public events. Archives of General Psychiatry 57, 581-590.
303. Llorca PM, Azorin JM, Despiegel N, et al. (2005) Efficacy of escitalopram in patients with severe depression: A pooled analysis. International Journal of Clinical Practice 59, 268-275.
304. Loo H and Deniker P (1988) Position of tianeptine among antidepres-sive chemotherapies. Clinical Neuropharmacology 11 (Suppl 2), S97-102.
305. Loosen PT and Prange AJ, Jr. (1982) Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: A review. American Journal of Psychiatry 139, 405-416.
306. Lucena MI, Carvajal A, Andrade RJ, et al. (2003) Antidepressant-induced hepatotoxicity. Expert Opinion on Drug Safety 2, 249-262.
307. Lucki I, Dalvi A, and Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl.). 155, 315-322.
308. Ludwig J and Marcotte DE (2005) Anti-depressants, suicide, and drug regulation. Journal of Policy Analysis and Management 24, 249-272.
309. Lupien SJ, de Leon M, de Santi S, et al. (1998) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience 1, 69-73.
310. Lynch DJ, Tamburrino MB, and Nagel R (1997) Telephone counseling for patients with minor depression: Preliminary findings in a family practice setting. Journal of Family Practice 44, 293-298.
311. Mace S and Taylor D (2000) Selective serotonin reuptake inhibitors: A review of efficacy and tolerability in depression. Expert Opinion in Pharmacotherapy 1, 917-933.
312. Mahajan T, Crown A, Checkley S, et al. (2004) Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. European Journal of Endocrinology/European Federation of Endocrine Societies 151, 325-332.
313. Mahmoud RA, Pandina GJ, Turkoz I, et al. (2007) Risperidone for treatment-refractory major depressive disorder: A randomized trial. Annals of Internal Medicine 147, 593-602.
314. Malatynska E and Knapp RJ (2005) Dominant-submissive behavior as models of mania and depression. Neuroscience and Biobehavioral Reviews 29, 715-737.
315. Malatynska E and Kostowski W (1984) The effect of antidepressant drugs on dominance behavior in rats competing for food. Polish Journal of Pharmacology and Pharmacy 36, 531-540.
316. Malberg JE, Eisch AJ, Nestler EJ, et al. (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience 20, 9104-9110.
317. Mangweth B, Hudson JI, Pope HG, et al. (2003) Family study of the aggregation of eating disorders and mood disorders. Psychological Medicine 33, 1319-1323.
318. Mann K, Hiemke C, Schmidt LG, et al. (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Therapeutic Drug Monitoring 28, 83-88.
319. Marcus SM, Young EA, Kerber KB, et al. (2005) Gender differences in depression: Findings from the STAR*D study. Journal of Affective Disorders 87, 141-150.
320. Martiny K, Lunde M, Unden M, et al. (2005) Adjunctive bright light in non-seasonal major depression: Results from clinician-rated depression scales. Acta Psychiatrica Scandinavica 112, 117-125.
321. McArthur R and Borsini F (2006) Animal models of depression in drug discovery: A historical perspective. Pharmacology, Biochemistry and Behavior 84, 436-452.
322. McEwen BS and Olie JP (2005) Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: Tianeptine. Molecular Psychiatry 10, 525-537.
323. McLean DE and Link BG (1994) Stress and Mental Health. Contemporary Issues and Prospects for the Future. Avison WR and Gotlib IH (eds). Plenum Press, New York, NY, USA, pp 15-442.
324. Medicines and Healthcare products Regulatory Agency (2006): Updated prescribing advice for venlafaxine: Information for healthcare professionals. http://www.mhra.gov.uk/home/ideplg?dcservice=SS_GET_PAGE&SSDOCName=CON202386&SSSourceNodeld=242&SSTargetNodeld=221
325. Menza M, Marin H, Kaufman K, et al. (2004) Citalopram treatment of depression in Parkinson's disease: The impact on anxiety, disability, and cognition. Journal of Neuropsychiatry and Clinical Neurosciences 16, 315-319.
326. Mercante JP, Peres MF, Guendler V, et al. (2005) Depression in chronic migraine: Severity and clinical features. Arquivos De Neuro-Psiquiatria 63, 217-220.
327. Miklowitz DJ, George EL, Richards JA, et al. (2003) A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Archives of General Psychiatry 60, 904-912.
328. Millan MJ, Gobert A, Newman-Tancredi A, et al. (2000) S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)-and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. Journal of Pharmacology and Experimental Therapeutics 292, 38-53.
329. Miller L and Griffith J (1983) A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl.) 80, 199-205.
330. Minov C, Baghai TC, Schule C, et al. (2001) Serotonin-2A-receptor and-transporter polymorphisms: Lack of association in patients with major depression. Neuroscience Letters 303, 119-122.
331. Miovic M and Block S (2007) Psychiatric disorders in advanced cancer. Cancer 110, 1665-1676.
332. Mitchell AJ and Subramaniam H (2005) Prognosis of depression in old age compared to middle age: A systematic review of comparative studies. American Journal of Psychiatry 162, 1588-1601.
333. Möller HJ (2006a) Is there evidence for negative effects of antidepressants on suicidality in depressive patients? European Archives of Psychiatry and Clinical Neuroscience, 256, 476-496.
334. Möller HJ (2006b) Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. European Archives of Psychiatry and Clinical Neuroscience 256, 329-343.
335. Montgomery DB, Roberts A, Green M, et al. (1994) Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. European Archives of Psychiatry and Clinical Neuroscience 244, 211-215.
336. Montgomery SA (1998) Chairman's overview. The place of reboxetine in antidepressant therapy. Journal of Clinical Psychiatry 59 (Suppl. 14), 26-29.
337. Montgomery SA (1995) Safety of mirtazapine: A review. International Clinical Psychopharmacology 10(Suppl.) 4, 37-45.
338. Montgomery SA (2005) Antidepressants and seizures: Emphasis on newer agents and clinical implications. International Journal of Clinical Practice 59, 1435-1440.
339. Montgomery SA and Asberg M (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
340. Montgomery SA and Kasper S (2007) Severe depression and antidepressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology 22, 283-291.
341. Montgomery SA, Kennedy SH, Burrows GD, et al. (2004) Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology 19, 271-280.
342. Moscicki EK (1999) The Harvard Medical School guide to suicide assessment and intervention. Jacobs D (ed). Jossey-Bass, San Francisco, pp 40-51.
343. Moskowitz H and Burns M (1986) Cognitive performance in geriatric subjects after acute treatment with antidepressants. Neuropsychobiology 15 (Suppl 1), 38-43.
344. Mosolov SN (1998) Clinical pharmacology of antidepressants (review). Ter-apevticheskii Arkhiv 70, 71-76.
345. Mottram P, Wilson K, and Strobl J (2006) Antidepressants for depressed elderly. The Cochrane Database of Systematic Reviews [Computer File] CD003491.
346. Mueller TI and Leon AC (1996) Recovery, chronicity, and levels of psychopathology in major depression. Psychiatric Clinics of North America 19, 85-102.
347. Muller MB, Toschi N, Kresse et al. (2000) Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neuro-trophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain. Neuropsychopharmacology 23, 205-215.
348. Muller N and Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Molecular Psychiatry
349. Müller-Oerlinghausen B, Ahrens B, and Felber W (2006) Lithium in Neuropsychiatry-The Comprehensive Guide.Bauer M, Grof P, and Müller-Oerlinghausen B (eds). Informa Healthcare, Oxfordshire, UK.
350. Mulsant BH, Sweet RA, Rosen J, et al. (2001) A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. Journal of Clinical Psychiatry 62, 597-604.
351. Naguib M and Koorn R (2002) Interactions between psychotropics, anaesthetics and electroconvulsive therapy: Implications for drug choice and patient management. CNS Drugs 16, 229-247.
352. Narushima K, Paradiso S, Moser DJ, et al. (2007) Effect of antidepressant therapy on executive function after stroke. British Journal of Psychiatry 190, 260-265.
353. National Institute for Health and Clinical Excellence (2004): CG23 Depression: NICE guideline. http://www.nice.org.uk/page.aspx?o=cg023niceguideline
354. National Institute of Mental Health (1976) 028 CGI. Clinical Global Impressions. In Manual for the EDCEU Assessment Battery, 2. Rev, Guy W and Bonato RR (ed). Chevy Chase, MD, USA, pp 12-1-12-6.
355. Nease DE Jr. and Maloin JM (2003) Depression screening: A practical strategy. Journal of Family Practice 52, 118-124.
356. Nelson JC (2000) Augmentation strategies in depression 2000. Journal of Clinical Psychiatry. 61 (Suppl. 2), 13-19.
357. Nemeroff CB (1996a) The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Molecular Psychiatry 1, 336-342.
358. Nemeroff CB (1996b) The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Molecular Psychiatry 1, 336-342.
359. Nemeroff CB and Owens MJ (2004) Pharmacologic differences among the SSRIs: Focus on monoamine transporters and the HPA axis. CNS Spec-trums 9, 23-31.
360. Nemeroff CB, Widerlöv E, Bisette G, et al. (1984) Elevated concentrations of CSF corticotropin-releasingfactor-like immunoreactivity in depressed patients. Science 226, 1342-1343.
361. Nemets B, Bersudsky Y, and Belmaker RH (2005) Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. Journal of Clinical Psychiatry 66, 586-590.
362. Nemets B, Stahl Z, and Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 159, 477-479.
363. Nestler EJ, Gould E, Manji H, et al. (2002) Preclinical models: Status of basic research in depression. Biological Psychiatry. 52, 503-528.
364. Nezu AM and Perri MG (1989) Social problem-solving therapy for unipolar depression: An initial dismantling investigation. Journal of Consulting and Clinical Psychology 57, 408-413.
365. Nierenberg AA, Petersen TJ, and Alpert JE (2003) Prevention of relapse and recurrence in depression: The role of long-term pharmacotherapy and psychotherapy. Journal of Clinical Psychiatry 64 (Suppl. 15), 13-17.
366. Nierenberg AA, Fava M, Trivedi MH, et al. (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. American Journal of Psychiatry 163, 1519-1530.
367. Nierenberg AA, Trivedi MH, Fava M, et al. (2007) Family history of mood disorder and characteristics of major depressive disorder: A STAR(*)D (sequenced treatment alternatives to relieve depression) study. Journal of Psychiatric Research 41, 214-221.
368. Nilsson FM and Kessing LV (2004) Increased risk of developing stroke for patients with major affective disorder-a registry study. European Archives of Psychiatry and Clinical Neuroscience 254, 387-391.
369. Normann C, Hummel B, Scharer LO, et al. (2002) Lamotrigine as adjunct to paroxetine in acute depression: A placebo-controlled, double-blind study. Journal of Clinical Psychiatry 63, 337-344.
370. Novalis P, Rojcewicz S, and Peele R (1993) Clinical Manual of Supportive Psychotherapy. American Psychiatric Publishing, Arlington, VA.
371. Novick JS, Stewart JW, Wisniewski SR, et al. (2005) Clinical and demographic features of atypical depression in outpatients with major depressive disorder: Preliminary findings from STAR*D. Journal of Clinical Psychiatry 66, 1002-1011.
372. Nowak G, Ordway GA, and Paul IA (1995) Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Research 675, 157-164.
373. Olver JS, Burrows GD, and Norman TR (2001) Third-generation antidepressants: Do they offer advantages over the SSRIs? CNS Drugs 15, 941-954.
374. Ostacher MJ, Huffman J, Perlis R, et al. (2005) Evidence-based pharmacotherapy of major depressive disorder. In Evidence-Based Psychopharmacology, Stein DJ, Lerer B, and Stahl SM (eds). Camebridge University Press, Camebridge, pp 1-21.
375. Ownby RL, Crocco E, Acevedo A, et al. (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Archives of General Psychiatry 63, 530-538.
376. Ozcanli T, Unsalver B, Ozdemir S, et al. (2005) Sertraline-and mirtazapine-induced severe neutropenia. American Journal of Psychiatry 162, 1386.
377. Pacher P, Ungvari Z, Nanasi PP, et al. (1999) Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Current Medicinal Chemistry 6, 469-480.
378. Paddock S, Laje G, Charney D, et al. (2007) Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. American Journal of Psychiatry 164, 1181-1188.
379. Pampallona S, Bollini P, Tibaldi G, et al. (2004) combined pharmacotherapy and psychological treatment for depression: A systematic review. Archives of General Psychiatry 61, (7), 714-719.
380. Papakostas GI (2006) Dopaminergic-based pharmacotherapies for depression. European Neuropsychopharmacology 16, 391-402.
381. Papakostas GI, Nelson JC, Kasper S, et al. (2007a) A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. European Neuropsychopharmacology.
382. Papakostas GI, Shelton RC, Smith J, et al. (2007b) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis. Journal of Clinical Psychiatry 68, 826-831.
383. Parmelee PA, Katz IR, and Lawton MP (1989) Depression among institutionalized aged: Assessment and prevalence estimation. Journal of Gerontology 44, M22-M29.
384. Patten S, Cipriani A, Brambilla P, et al. (2005) International dosage differences in fluoxetine clinical trials. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 50, 31-38.
385. Patten SB and Barbui C (2004) Drug-induced depression: A systematic review to inform clinical practice. Psychotherapy and Psychosomatics 73, 207-215.
386. Patten SB and Lamarre CJ (1992) Can drug-induced depressions be identified by their clinical features? Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 37, 213-215.
387. Patten SB and Metz LM (1997) Depression in multiple sclerosis. Psychotherapy and Psychosomatics 66, 286-292.
388. Patten SB, Sedmak B, Russell ML (2001) Major depression: Prevalence, treatment utilization and age in Canada. Canadian Journal of Clinical Pharmacology 8, 133-138.
389. Pavlovic DM and Milovic AM (1999) [Clinical characteristics and therapy of neurosyphilis in patients who are negative for human immunodeficiency virus]. Srpski Arhiv Za Celokupno Lekarstvo 127, 236-240.
390. Paykel ES (2001) Continuation and maintenance therapy in depression. British Medical Bulletin 57, 145-159.
391. Payne JL (2003) The role of estrogen in mood disorders in women. International Review of Psychiatry 15, 280-290.
392. Peet M and Horrobin DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry 59, 913-919.
393. Penninx BW, Beekman AT, Honig A, et al. (2001) Depression and cardiac mortality: Results from a community-based longitudinal study. Archives of General Psychiatry 58, 221-227.
394. Petrides G, Fink M, Husain MM, et al. (2001) ECT remission rates in psychotic versus nonpsychotic depressed patients: A report from CORE. Journal of ECT 17, 244-253.
395. Pezawas L, Angst J, and Kasper S (2005) Recurrent brief depression revisited. International Review of Psychiatry 17, 63-70.
396. Pezawas L, Stamenkovic M, and Kasper S (2001) [Recurrent brief depressive episodes. Epidemiology, clinical aspects, diagnosis and therapy]. Nerve-narzt 72, 169-180.
397. Pfaff JJ and Almeida OP (2005) Detecting suicidal ideation in older patients: Identifying risk factors within the general practice setting. British Journal of General Practice 55, 269-273.
398. Phillips SD and Ringo P (1995) Phenelzine and venlafaxine interaction. American Journal of Psychiatry 152, 1400-1401.
399. Pineyro G, Deveault L, Blier P, et al. (1995a) Effect of acute and prolonged tianeptine administration on the 5-HT transporter: Electrophysiological, biochemical and radioligand binding studies in the rat brain. Naunyn-Schmiedebergs Archives of Pharmacology 351, 111-118.
400. Pineyro G, Deveault L, de MC, et al. (1995b) Effect of prolonged administration of tianeptine on 5-HT neurotransmission: An electrophysiological study in the rat hippocampus and dorsal raphe. Naunyn-Schmiedebergs Archives of Pharmacology 351, 119-125.
401. Pinquart M, Duberstein PR, and Lyness JM (2006) Treatments for later-life depressive conditions: A meta-analytic comparison of pharmacotherapy and psychotherapy. American Journal of Psychiatry 163, 1493-1501.
402. Pinto-Meza A, Usall J, Serrano-Blanco A, et al. (2006) Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? Journal of Affective Disorders 93, 53-60.
403. Pisani F, Spina E, and Oteri G (1999) Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice. Epilepsia 40 (Suppl. 10), S48-S56.
404. Pope HG, Jr., Cohane GH, Kanayama G, et al. (2003) Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. American Journal of Psychiatry 160, 105-111.
405. Porche DJ and Willis DG (2006) Depression in HIV-infected men. Issues in Mental Health Nursing 27, 391-401.
406. Porsolt RD (2000) Animal models of depression: Utility for transgenic research. Review of Neuroscience 11, 53-58.
407. Preisig M, Fenton BT, Stevens DE, et al. (2001) Familial relationship between mood disorders and alcoholism. Comprehensive Psychiatry 42, 87-95.
408. Puech A, Montgomery SA, Prost JF, et al. (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. International Clinical Psychopharmacology 12, 99-108.
409. Puech AJ, Rioux P, Poncelet M, et al. (1981) Pharmacological properties of new antipsychotic agents: Use of animal models. Neuropharmacology 20, 1279-1284.
410. Purebl G, Birkas E, Csoboth C, et al. (2006) The relationship of biological and psychological risk factors of cardiovascular disorders in a large-scale national representative community survey. Behavioral Medicine 31, 133-139.
411. Quitkin FM, McGrath PJ, Stewart JW, et al. (2005) Remission rates with 3 consecutive antidepressant trials: Effectiveness for depressed outpatients. Journal of Clinical Psychiatry 66, 670-676.
412. Rabheru K (2001) The use of electroconvulsive therapy in special patient populations. canadian Journal of Psychiatry. Revue Canadienne De Psy-chiatrie 46, 710-719.
413. Ramana R, Paykel ES, Cooper Z, et al. (1995) Remission and relapse in major depression: A two-year prospective follow-up study. Psychological Medicine 25, 1161-1170.
414. Rampello L, Chiechio S, Nicoletti G, et al. (2004) Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl) 173, 73-78.
415. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. (2006) Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Archives of General Psychiatry 63, 161-167.
416. Reagan LP, Rosell DR, Wood GE, et al. (2004) Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine. Proceedings of the National Academy of Sciences of the United States of America 101, 2179-2184.
417. Rees AM, Austin MP, and Parker G (2005) Role of omega-3 fatty acids as a treatment for depression in the perinatal period. Australian and New Zealand Journal of Psychiatry 39, 274-280.
418. Regier DA, Farmer ME, Rae DS, et al. (1993) One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment Area study. Acta Psychiatrica Scan-dinavica 88, 35-47.
419. Rickards H (2005) Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. Journal of Neurology, Neurosurgery and Psychiatry 76 (Suppl. 1), 148-152.
420. Riemann D, Wiegand M, Lauer CJ, et al. (1993) Naps after total sleep deprivation in depressed patients: Are they depressiogenic? Psychiatry Research 49, 109-120.
421. Rigby M, O'Donnell R, and Rupniak NM (2005) Species differences in tachykinin receptor distribution: Further evidence that the substance P (NK1) receptor predominates in human brain. Journal of Comparative Neurology 490, 335-353.
422. Robichaud M, Beauchemin V, Lavoie N, et al. (2001) Effects of bilateral olfactory bulbectomy on N-methyl-D-aspartate receptor function: Autoradiographic and behavioral studies in the rat. Synapse. 42, 95-103.
423. Rodriguez C and Puerta G (1997) Prevalencia de dintomas de depresion y ansiedad en los pacientes de consulta no psiquiatrica. Rev Col Psiquiatria XXVI, 273-288.
424. Rohland BM, Carroll BT, and Jacoby RG (1993) ECT in the treatment of the catatonic syndrome. Journal of Affective Disorders 29, 255-261.
425. Rosenbaum JF, Fava M, Hoog SL, et al. (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry 44, 77-87.
426. Rothschild AJ (1996) Management of psychotic, treatment-resistant depression. Psychiatric Clinics of North America 19, 237-252.
427. Ruhe HG, Mason NS, and Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A metaanalysis of monoamine depletion studies. Molecular Psychiatry 12, 331-359.
428. Rupprecht R (2003) Neuroactive steroids: Mechanisms of action and neu-ropsychopharmacological properties. Psychoneuroendocrinology 28, 139-168.
429. Rupprecht R, Rupprecht C, Rupprecht M, et al. (1989) Triiodothyronine, thyroxine, and TSH response to dexamethasone in depressed patients and normal controls. Biological Psychiatry 25, 22-32.
430. Rush AJ (1999) Strategies and tactics in the management of maintenance treatment for depressed patients. Journal of Clinical Psychiatry 60(Suppl. 14), 21-26; discussion 31-35, 21-26.
431. Rush AJ (2007) Limitations in efficacy of antidepressant monotherapy. Journal of Clinical Psychiatry 68 (Suppl. 10), 8-10.
432. Rush AJ, Kraemer HC, Sackeim HA, et al. (2006a) Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31, 1841-1853.
433. Rush AJ, Thase ME, and Dube S (2003) Research issues in the study of difficult-to-treat depression. Biological Psychiatry 53, 743-753.
434. Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006b) Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry 163, 1905-1917.
435. Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006c) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 1231-1242.
436. Rush AJ, Zimmerman M, Wisniewski SR, et al. (2005) Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. Journal of Affective Disorders 87, 43-55.
437. Sackeim HA, Haskett RF, Mulsant BH, et al. (2001) Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial. Journal of the American Medical Association. 285, 1299-1307.
438. Samuelian JC and Hackett D (1998) A randomized, double-blind, paral-lel-group comparison of venlafaxine and clomipramine in outpatients with major depression. Journal of Psychopharmacology 12, 273-278.
439. Sanacora G, Gueorguieva R, Epperson CN, et al. (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 61, 705-713.
440. Sanacora G, Kendell SF, Levin Y, et al. (2007) Preliminary evidence of rilu-zole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry. 61, 822-825.
441. Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Archives of General Psychiatry 57, 925-935.
442. Sartorius A, Baghai T, Barett B, et al. (2007) Antidepressant medications and other treatments of depressive disorders-A CINP task force report based on a review of evidence. International Journal of Neuropsychopharmacology Ref Type: In Press.
443. Sartorius A and Henn FA (2005) Continuation ECT. Psychiatrische Praxis 32, 408-411.
444. Sartorius N (1986) Cross-cultural research on depression. Psychopathology 19 (Suppl. 2), 6-11.
445. Sartorius N (2001) The economic and social burden of depression. Journal of Clinical Psychiatry 62 (Suppl. 15), 8-11.
446. Schaefer M, Engelbrecht MA, Gut O, et al. (2002) Interferon alpha (IFNal-pha) and psychiatric syndromes: A review. Prog. Neuropsychopharmacol. Biological Psychiatry 26, 731-746.
447. Schatzberg AF, Blier P, Delgado PL, et al. (2006) Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research. Journal of Clinical Psychiatry 67 (Suppl 4), 27-30.
448. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry 122, 509-522.
449. Schillevoort I, van Puijenbroek EP, de BA, et al. (2002) Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: A case-control study using spontaneous reports. International Clinical Psychopharmacology 17, 75-79.
450. Schindler F and Anghelescu IG (2007) Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: A randomized, open-label study. International Clinical Psychopharmacology 22, 179-182.
451. Schuurman AG, Van den AM, Ensinck KT, et al. (2002) Increased risk of Parkinson's disease after depression: A retrospective cohort study. Neurology 58, 1501-1504.
452. Schweiger U, Deuschle M, Weber B, et al. (1999) Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosomatic Medicine 61, 292-296.
453. Seligman MEP (1975) Helplessness: On Depression, Development and Death. WH Freeman, San Francisco.
454. Serebruany VL (2006) Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something? American Journal of Medicine 119, 113-116.
455. Serretti A, Artioli P, Quartesan R (2005) Pharmacogenetics in the treatment of depression: Pharmacodynamic studies. Pharmacogenetics Genomics 15, 61-67.
456. Serretti A, Cusin C, Lattuada E, et al. (1999) Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders A Serrettia, C Cusin, E Lattuada, D Di Bella, M Catalano and E Smeraldi. Molecular Psychiatry 4, 280-283.
457. Sharan P and Saxena S (1998) Treatment-resistant depression: Clinical significance, concept and management. National Medical Journal of India 11, 69-79.
458. Shea MT, Glass DR, and Pilkonis PA (1987) Frequency and implications of personality disorder in a sample of depressed outpatients. Journal of Personality Disorders 1, 27-42.
459. Shea MT, Widiger TA, and Klein MH (1992) Comorbidity of personality disorders and depression: Implications for treatment. Journal of Consulting and Clinical Psychology 60, 857-868.
460. Shelton RC, Keller MB, Gelenberg A, et al. (2001) Effectiveness of St John's wort in major depression: A randomized controlled trial. Journal of the American Medical Association 285, 1978-1986.
461. Shelton RC, Williamson DJ, Corya SA, et al. (2005) Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance. Journal of Clinical Psychiatry. 66, 1289-1297.
462. Shimbo D, Davidson KW, Haas DC, et al. (2005) Negative impact of depression on outcomes in patients with coronary artery disease: Mechanisms, treatment considerations, and future directions. Journal of Thrombosis and Haemostasis. 3, 897-908.
463. Shore PA, Silver SL, and Brodie BB (1955) Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science 122, 284-285.
464. Shores MM, Sloan KL, Matsumoto AM, et al. (2004) Increased incidence of diagnosed depressive illness in hypogonadal older men. Archives of General Psychiatry 61, 162-167.
465. Silvers KM, Woolley CC, Hamilton FC, et al. (2005) Randomised doubleblind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukotrienes and Essential Fatty Acids 72, 211-218.
466. Simon GE, VonKorff M, Piccinelli M, et al. (1999) An international study of the relation between somatic symptoms and depression. New England Journal of Medicine 341, 1329-1335.
467. Sokolski KN, Conney JC, Brown BJ, et al. (2004) Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Research 125, 81-86.
468. Song C and Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neuroscience and Biobehavioral Reviews 29, 627-647.
469. Spencer SS, Berg AT, Vickrey BG, et al. (2003) Initial outcomes in the Multicenter Study of Epilepsy Surgery. Neurology 61, 1680-1685.
470. Stahl SM (1997) Psychopharmacology of Antidepressants. Martin Dunitz Ltd., London, UK.
471. Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. Journal of Affective Disorders 51, 215-235.
472. Stahl SM (2006) Essential Psychopharmacology: The Prescriber's Guide. Camebridge University Press, Camebridge.
473. Stahl SM (2001) Effects of estrogen on the central nervous system. Journal of Clinical Psychiatry 62, 317-318.
474. Stahl SM, Grady MM, Moret C, et al. (2005) SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 10, 732-747.
475. Steinacher L, Vandel P, Zullino DF, et al. (2002) Carbamazepine augmentation in depressive patients non-responding to citalopram: A pharmacokinetic and clinical pilot study. European Neuropsychopharmacology 12, 255-260.
476. Stewart C and Reid I (1993) Electroconvulsive stimulation and synaptic plasticity in the rat. Brain Research 620, 139-141.
477. Stotz G, Woggon B, and Angst J (1999) Psychostimulants in the therapy of treatment-resistant depression. Review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues in Clinical Neuroscience 1, 165-174.
478. Stout SC, Owens MJ, and Nemeroff CB (2001) Neurokinin(1) receptor antagonists as potential antidepressants. Annual Review of Pharmacology and Toxicology. 41, 877-906.
479. Sullivan PF, Neale MC, and Kendler KS (2000) Genetic epidemiology of major depression: Review and meta-analysis. American Journal of Psychiatry 157, 1552-1562.
480. Szegedi A and Schwertfeger N (2005) Mirtazapine: A review of its clinical efficacy and tolerability. Expert Opinion in Pharmacotherapy. 6, 631-641.
481. Taylor CB, Youngblood ME, Catellier D, et al. (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Archives of General Psychiatry 62, 792-798.
482. Taylor MA and Fink M (2003) Catatonia in psychiatric classification: A home of its own. American Journal of Psychiatry 160, 1233-1241.
483. Taylor MJ, Carney SM, Goodwin GM, et al. (2004) Folate for depressive disorders: Systematic review and meta-analysis of randomized controlled trials. Journal of Psychopharmacology 18, 251-256.
484. Teasdale JD, Fennell MJ, Hibbert GA, et al. (1984) Cognitive therapy for major depressive disorder in primary care. British Journal of Psychiatry 144, 400-6.
485. Terman M (2007) Evolving applications of light therapy. Sleep Medicine Reviews(11) 6, 497-507.
486. Terman M and Terman JS (2005) Light therapy for seasonal and nonsea-sonal depression: Efficacy, protocol, safety, and side effects. CNS Spec-trums 10, 647-663.
487. Thase ME (1999) Antidepressant treatment of the depressed patient with insomnia. Journal of Clinical Psychiatry 60 (Suppl. 17), 28-31.
488. Thase ME, Baker RA, Simmons JH, et al. (2006a) Effects of mirtazapine versus SSRIs on core symptoms of depression. Journal of Affective Disorders 91(S1), abstract.
489. Thase ME, Greenhouse JB, Frank E, et al. (1997) Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry 54, 1009-1015.
490. Thase ME, Shelton RC, and Khan A (2006b) Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: A randomized comparison of standard-and higher-dosing strategies. Journal of Clinical Psychopharmacology 26, 250-258.
491. Thome J, Duman RS, and Henn FA (2002) Molecular aspects of antidepres-sive therapy. Transsynaptic effects on signal transduction, gene expression and neuronal plasticity. Nervenarzt 73, 595-599.
492. Tran PV, Bymaster FP, McNamara RK, et al. (2003) Dual monoamine modulation for improved treatment of major depressive disorder. Journal of Clinical Psychopharmacology 23, 78-86.
493. Trautmann-Sponsel RD and Dienel A (2004) Safety of Hypericum extract in mildly to moderately depressed outpatients: A review based on data from three randomized, placebo-controlled trials. Journal of Affective Disorders 82, 303-307.
494. Trenque T, Piednoir D, Frances C, et al. (2002) Reports of withdrawal syndrome with the use of SSRIs: A case/non-case study in the French Pharmacovigilance database. Pharmacoepidemiology and Drug Safety 11, 281-283.
495. Trivedi MH, Fava M, Wisniewski SR, et al. (2006) Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354, 1243-1252.
496. Tylee A (2006) Identifying and managing depression in primary care in the United Kingdom. Journal of Clinical Psychiatry 67 (Suppl. 6), 41-45.
497. Uchida H, Takeuchi H, Suzuki T, et al. (2005) Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. Journal of Clinical Psychopharmacology 25, 545-551.
498. U.S. Food and Drug Administration (2005) Templates for Antidepressant Black Box Warning and Medication Guide Posted on FDA website http://www.fda.gov/drug/antidepressants/antidepressants_MG
499. Van Amerongen AP, Ferrey G, and Tournoux A (2002) A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Journal of Affective Disorders 72, 21-31.
500. van den Broek WW (2005) The practice guideline 'Depressive disorder' (first revision) from the Dutch College of General Practitioners; a response from the perspective of psychiatry. Nederlands Tijdschrift Voor Geneeskunde 149, 509-510.
501. Vis PM, van BM, and Einarson TR (2005) Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: A meta-analysis of randomized clinical trials. Annals of Pharmacotherapy 39, 1798-1807.
502. Walsh BT and Sysko R (2005) Placebo control groups in trials of major depressive disorder among older patients. Journal of Clinical Psychopharmacology 25 (Suppl.), 29-33.
503. Wang PS, Schneeweiss S, Brookhart MA, et al. (2005) Suboptimal antidepressant use in the elderly. Journal of Clinical Psychopharmacology 25, 118-126.
504. Ware MR (1997) Fluvoxamine: A review of the controlled trials in depression. Journal of Clinical Psychiatry 58 (Suppl. 5), 15-23.
505. Wedding U, Koch A, Rohrig B, et al. (2007) Requestioning depression in patients with cancer: Contribution of somatic and affective symptoms to Beck's Depression Inventory. Annals of Oncology.
506. Ween JE (2005) Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function. Evid Based Mental Health 8, 74.
507. Weiss SR and Post RM (1998) Kindling: Separate vs. shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 38, 167-180.
508. Weissman MM, Markowitz JC, and Klerman GL (2000) Comprehensive Guide to Interpersonal Psychotherapy. Basic Books, New York, NY USA.
509. Wen SW, Yang Q, Garner P, et al. (2006) Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology 194, 961-966.
510. Wharton RN, Perel JM, Dayton PG, et al. (1971) A potential clinical use for methylphenidate with tricyclic antidepressants. American Journal of Psychiatry 127, 1619-1625.
511. Whitehead C, Moss S, Cardno A, et al. (2002) Antidepressants for people with both schizophrenia and depression. The Cochrane Database of Systematic Reviews [Computer File] CD002305.
512. Wilde MI and Benfield P (1995) Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 49, 411-439.
513. Williams DR, Gonzalez HM, Neighbors H, et al. (2007) Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: Results from the National Survey of American Life. Archives of General Psychiatry 64, 305-315.
514. Willner P (1986) Validation criteria for animal models of human mental disorders: Learned helplessness as a paradigm case. Progress in NeuroPsychopharmacology and Biological Psychiatry 10, 677-690.
515. Wilson K, Mottram P, Sivanranthan A, et al. (2001) Antidepressant versus placebo for depressed elderly. The Cochrane Database of Systematic Reviews [Computer File] CD000561.
516. Winkler D, Pjrek E, and Kasper S (2005) Anger attacks in depression-evidence for a male depressive syndrome. Psychotherapy and Psychoso-matics 74, 303-307.
517. Winsky L and Brady L (2005) Perspective on the status of preclinical models for psychiatric disorders. Drug Discovery Today: Disease Models 2, 279-283.
518. Winston A, Rosenthal R, and Pinsker H (2004) Introduction to Supportive Psychotherapy. American Psychiatric Publishing, Arlington, VA, USA.
519. Wirz-Justice A, Benedetti F, Berger M, et al. (2005) Chronotherapeutics (light and wake therapy) in affective disorders. Psychological Medicine 35, 939-944.
520. Wisner KL, Gelenberg AJ, Leonard H, et al. (1999) Pharmacologic treatment of depression during pregnancy. Journal of the American Medical Association 282, 1264-1269.
521. Wisner KL, Zarin DA, Holmboe ES, et al. (2000) Risk-benefit decision making for treatment of depression during pregnancy. American Journal of Psychiatry 157, 1933-1940.
522. Wolf NJ and Hopko DR (2007) Psychosocial and pharmacological interventions for depressed adults in primary care: A critical review. Clin Psychol. Rev.
523. Wong ML and Licinio J (2001) Research and treatment approaches to depression. Nature Reviews Neuroscience 2, 343-351.
524. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland.
525. World Psychiatric Association (2006) WPA educational program on depressive disorder-module 2 (Depressive Disorders in Physical Illness). http://www.wpanet.org/sectorial/edu4a.html.
526. Wright JH and Small K (2005) Computer programs for cognitive-behavior therapy. In Encyclopedia of Cognitive Behavior Therapy, Freeman A, Felgoise S, Nezu C, et al. (eds). Springer Publishing, New York, NY USA, pp 130-133.
527. Wu JC and Bunney WE (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: Review and hypothesis. American Journal of Psychiatry 147, 14-21.
528. Yamada K, Yagi G, and Kanba S (2003) Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: A randomized controlled trial. Psychiatry and Clinical Neurosciences 57, 183-187.
529. Young EA, Midgley AR, Carlson NE, et al. (2000) Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. Archives of General Psychiatry 57, 1157-1162.
530. Zanardi R, Serretti A, Rossini D, et al. (2001) Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry 50, 323-330.
531. Zarate CA, Jr., Singh JB, Carlson PJ, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.
532. Zhang W, Perry KW, Wong DT, et al. (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23, 250-262.
533. Zimmerman M, McGlinchey JB, Posternak MA, et al. (2006) How Should Remission From Depression Be Defined? The Depressed Patient's Perspective. American Journal of Psychiatry 163, 148-150.
534. Zobel AW, Yassouridis A, Frieboes R-M, et al. (1999) Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. American Journal of Psychiatry 156, 949-951.
535. Zullino D and Baumann P (2001) Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34, 119-127.